ArticleiScience2024
Ubiquitin-specific peptidase 22 controls integrin-dependent cancer cell stemness and metastasis.
Abstract read
In one paragraph
Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape.The Journal of clinical investigation · 2026Article
- FBXO6 regulates colon cancer migration and invasion via ITGB1 ubiquitination and downstream signaling.Cell death & disease · 2026Article
- mFrontiers in immunology · 2026Review
- The mechanisms and therapeutic advances of interactions between breast cancer and cardiovascular diseases.Frontiers in pharmacology · 2026Review
- The impact of SRRM2-AS1 in ovarian cancer: a comprehensive analysis based on pan-cancer and in vitro validation.Discover oncology · 2025Article
- USP22 enhances atherosclerotic plaque stability and macrophage efferocytosis by stabilizing PPARγ.Communications biology · 2025Article
- Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.Biomolecules · 2025Review
- RBM15-mediated mFrontiers in cell and developmental biology · 2025Review
- Bioinformatic analysis of the role of USP22 expression in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2025Article
- Decoding the immunoregulatory functions of ALKBH5 in the tumor microenvironment.Frontiers in immunology · 2025Review
- Lactylation and tumor immune regulation: insights from recent studies.Frontiers in immunology · 2025Review
- Epinephrine promotes breast cancer metastasis through a ubiquitin-specific peptidase 22-mediated lipolysis circuit.Science advances · 2024Article
- The secoiridoid glycoside Gentiopicroside is a USP22 inhibitor with potent antitumor immunotherapeutic activity.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- ATXN3 functions as a tumor suppressor through potentiating galectin-9-mediated apoptosis in human colon adenocarcinoma.The Journal of biological chemistry · 2024Article
- Integrins in cancer stem cells.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
- Update of
Authors and funding
16 authors.
Kun LiuDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Qiong GaoDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Yuzhi JiaDepartment of Medicine, Hematology/Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Juncheng WeiDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Shuvam Mohan ChaudhuriDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Shengnan WangDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Amy TangDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Nikita Lavanya ManiDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Radhika IyerDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Yang ChengDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Beixue GaoDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Weiyuan LuDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Zhaolin SunCollege of Basic Medical Sciences, Dalian Medical University, Dalian 116044, P.R. China.
Bin ZhangDepartment of Medicine, Hematology/Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Huiping LiuDepartment of Pharmacology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Deyu FangDepartment of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Funding
Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene TranscriptionR01DK120330 · NIDDK · UNIVERSITY OF VIRGINIA · PI Deyu Fang, Ling Qi · 2018 to 2026
$4.9MA deubiquitination module controls Treg adaptation to tumor microenvironmentR01CA257520 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU, ZHANG, BIN · 2021 to 2025
$2.8MRegulation of Rhythmic m6A RNA Modification by ER‐associated DegradationR01DK126908 · NIDDK · WAYNE STATE UNIVERSITY · PI FANG, DEYU, ZHANG, KEZHONG · 2021 to 2024
$2.2MMolecular mechanisms underlying circulating tumor cell aggregationR01CA245699 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LIU, HUIPING · 2020 to 2024
$2.0MTargeting a Treg deubiquitinase in antitumor immune therapyR01CA232347 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU · 2018 to 2022
$1.7MChemistry of Life Processes Predoctoral Training ProgramT32GM149439 · NIGMS · NORTHWESTERN UNIVERSITY · PI NEIL L KELLEHER · 2023 to 2026
$1.6MA streamlined platform for phosphoproteome mapping of human tissuesUG3CA256967 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI LIU, HUIPING, SHI, TUJIN · 2020 to 2021
$800kNCI NIH HHS R01 CA232347NCI NIH HHS R01 CA245699NCI NIH HHS R01 CA257520NCI NIH HHS UG3 CA256967NIDDK NIH HHS R01 DK120330NIDDK NIH HHS R01 DK126908NIGMS NIH HHS T32 GM149439
Abstract
Integrins play critical roles in connecting the extracellular matrix and actin. While the upregulation of integrins is thought to promote cancer stemness and metastasis, the mechanisms underlying their upregulation in cancer stem cells (CSCs) remain poorly understood. Herein, we show that USP22 is essential in maintaining breast cancer cell stemness by promoting the transcription of integrin β1 (
Indexed as
CancerCell biologyMolecular biology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.